shutterstock_1905552877_nitpicker
nitpicker / Shutterstock.com
4 November 2021GenericsAlex Baldwin

EPO upholds Bayer's Xarelto dosage patents

Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office (EPO), the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto (rivaroxaban).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 September 2019   Bayer and two Boston hospitals have joined forces in a chronic lung disease research product, with the trio championing the ‘joint lab’ model as a blueprint for pharmaceutical research.
Americas
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.
Biotechnology
19 January 2023   Cohausz & Florack has added two new partners to the team to further expand the firm’s IP expertise in key technical areas.

More on this story

Americas
26 September 2019   Bayer and two Boston hospitals have joined forces in a chronic lung disease research product, with the trio championing the ‘joint lab’ model as a blueprint for pharmaceutical research.
Americas
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.
Biotechnology
19 January 2023   Cohausz & Florack has added two new partners to the team to further expand the firm’s IP expertise in key technical areas.

More on this story

Americas
26 September 2019   Bayer and two Boston hospitals have joined forces in a chronic lung disease research product, with the trio championing the ‘joint lab’ model as a blueprint for pharmaceutical research.
Americas
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.
Biotechnology
19 January 2023   Cohausz & Florack has added two new partners to the team to further expand the firm’s IP expertise in key technical areas.